FDA sends Novo Nordisk 2nd warning over GLP-1 ads for misleading claims in Ozempic promotion and risk disclosure violations.
Investing.com -- Novo Nordisk (CSE: NOVOb )shares rose more than 3% on Wednesday after the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results